

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 April 2023 (06.04.2023)



(10) International Publication Number
WO 2023/052415 A1

(51) International Patent Classification:

A61K 47/64 (2017.01) A61P 3/00 (2006.01)
A61P 3/10 (2006.01)

(21) International Application Number:

PCT/EP2022/076966

(22) International Filing Date:

28 September 2022 (28.09.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

21199346.4 28 September 2021 (28.09.2021) EP

(71) Applicant: **KØBENHAVNS UNIVERSITET** [DK/DK];
Norregade 10, 1165 Copenhagen K (DK).

(72) Inventors: **CLEMMENSEN, Christoffer**; c/o Københavns Universitet, Norregade 10, 1165 Copenhagen K (DK). **KLEIN, Anders Bue**; c/o Københavns Universitet, Norregade 10, 1165 Copenhagen K (DK). **PETERSEN,**

Jonas Odgaard; c/o Københavns Universitet, Norregade 10, 1165 Copenhagen K (DK). **SAKAMOTO, Kei**; c/o Københavns Universitet, Norregade 10, 1165 Copenhagen K (DK).

(74) Agent: **AWA DENMARK A/S**; Strandgade 56, 1401 Copenhagen K (DK).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: CONJUGATES OF GLUCAGON AND AMPK ACTIVATORS




Fig. 1

(57) Abstract: The present invention relates to a conjugated molecule comprising a peptide displaying at least 0.1 % activity of native glucagon at the glucagon receptor, and a AMP-activated protein kinase (AMPK) activator, the peptide being covalently bonded to the AMPK activator either directly or through a linker, the conjugated molecule for use in therapy, a pharmaceutical composition comprising the conjugated molecule, a method of reducing body weight of a mammal comprising administering the conjugated molecule to the mammal, and a non-therapeutic method of reducing body weight of a mammal comprising orally administering the conjugated molecule to the mammal.

[Continued on next page]

WO 2023/052415 A1

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*